Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of M1774 in Refractory SPOP-Mutant Prostate Cancer

NCT05828082 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05828082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05828082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of M1774 in Refractory SPOP-Mutant Prostate Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 16, 2023
Completion date
January 1, 2027
Enrollment
20 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate carcinoma, metastatic castration-resistant prostate carcinoma, refractory prostate carcinoma, stage ivb prostate cancer ajcc v8